Subcutaneous Infliximab Improves Crohn's Treatment Outcomes
A new study indicates that subcutaneous delivery of infliximab yields higher rates of remission for ileal Crohn's disease patients.
Updated on Oct. 23, 2026 in Nutrition
Live Poll
Do you trust newer drug delivery methods more than traditional hospital-administered IV treatments for chronic conditions?
Patients with ileal Crohn's disease showed superior clinical and endoscopic remission rates at week 54 when treated with subcutaneous infliximab compared to intravenous delivery. Researchers analyzed data from 200 total patients across four registrational trials to determine the efficacy of different delivery methods.
Why it matters
Understanding which delivery method optimizes drug response is critical for improving long-term care outcomes for patients with Crohn's disease. Researchers aimed to provide clarity on whether subcutaneous dosing provides a distinct clinical advantage for those suffering from the condition.
In a study of 200 patients, subcutaneous infliximab recipients achieved a 71.4% clinical remission rate compared to 51.4% for IV infliximab in the matched population. Serum concentrations of infliximab were also found to be higher among endoscopic responders.
The details
The study compared a 120 mg subcutaneous dose administered every 2 weeks against a 5 mg/kg IV dose given every 8 weeks. Researchers utilized propensity-score matching across 140 of the total participants to ensure an accurate comparison of clinical remission and endoscopic response rates.
Timeline
Clinical and endoscopic outcomes were measured at week 54.
The Big Picture
This study advances the current discourse on biologic administration presented at the American College of Gastroenterology (ACG) meeting. It highlights a critical shift in how clinicians assess the efficacy of drug delivery methods compared to traditional intravenous protocols.
Patients may see shifts in treatment recommendations as clinical evidence increasingly favors specific delivery protocols for managing ileal Crohn's disease. These findings could influence future care plans regarding whether a patient receives subcutaneous versus intravenous infusions.
The takeaway
These findings suggest that the delivery mechanism for biologic therapies plays a significant role in achieving deeper endoscopic remission. Patients should consult with their healthcare providers to discuss how current research on drug delivery may apply to their specific treatment routine.
Further reading
Learn more about the latest research in Nutrition.
Source note: This article includes information reported by Healio.
Live Poll
Do you trust newer drug delivery methods more than traditional hospital-administered IV treatments for chronic conditions?
